the

TEAM

Meet the visionaries behind Neuro-Kinesis’ unique product platform.

the

TECH

Explore Neuro-Kinesis’ advanced SMART Surgical Tool Technologies

the

TARGET

See how Neuro-Kinesis’ technology will enhance patient outcomes. 

Neuro-Kinesis is focused on creating next-generation surgical tools that incorporate our advanced biosensor technology that provides physicians and surgeons with real-time environmental monitoring that can greatly enhance a patient’s surgical outcome. 

NKC Fourth Quater SDevelopment Report Banner

Fourth Quarter 2022 Development Report

NKC has announced the completion of the Phase One development for its new Huygens™ Smart Catheter and Proteus™ Robotic Arm Platform.

Third Quarter 2022 Development Report Released

NKC has announced the completion of the Phase One development for its new Huygens™ Smart Catheter and Proteus™ Robotic Arm Platform.

Abbott Completes The Acquisition Of St. Jude Medical

NKC has announced the completion of the Phase One development for its new Huygens™ Smart Catheter and Proteus™ Robotic Arm Platform.

NKC Announces Upcoming Animal Study for Clinical Validation of its Huygens™ – Proteus™ Robotic Arm Surgical Platform

NKC has announced the completion of the Phase One development for its new Huygens™ Smart Catheter and Proteus™ Robotic Arm Platform.

Phase One Development Completed

NKC has announced the completion of the Phase One development for its new Huygens™ Smart Catheter and Proteus™ Robotic Arm Platform.

Frost & Sullivan Report on SBR Market

Global consulting firm Frost & Sullivan looks at potential market impact of the Neuro-Kinesis SmartBrain Retractor technology.

The SMART Tool Revolution

The development of SMART technologies for surgical tools coupled with advances in robotics is providing a revolution in creating better, safer and less invasive surgical options for patients.

Catheter Market Continues to Grow

The global catheter market expected to rise to $77.7B by 2026 with an average CAGR of 9.7% over the forecast period.

CGCI GLP Study Completed

The CGCI platform has successfully undergone a Good Laboratory Practice (GLP) animal study in advance of its next stage clinical trials.

CGCI Receives CE Marking for Sales in Europe

In December of 2011, the CGCI System received CE...

First-In-Man Clinical Trials For CGCI Completed

The key benefits and the safety and...

Article on CGCI Published in the Journal of American Heart Association

The Journal of the American Heart Association, a...

Dr. Eli Gang Ranked Among America’s Best Doctors

Dr. Eli Gang, M.D., Chief Operating Officer of...

CGCI Presented to International Congress

At the 2011 EHRA Europace Congress in Madrid,...

President of Madrid Inaugurates CGCI EP Suite

The inauguration of the electrophysiology lab at...

UL Certification Granted for CGCI

The CGCI Systcm received product certification...